Format

Send to

Choose Destination
Middle East Afr J Ophthalmol. 2013 Jan-Mar;20(1):26-37. doi: 10.4103/0974-9233.106384.

Nanotechnology approaches for ocular drug delivery.

Author information

1
Department of Ophthalmology, Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Abstract

Blindness is a major health concern worldwide that has a powerful impact on afflicted individuals and their families, and is associated with enormous socio-economical consequences. The Middle East is heavily impacted by blindness, and the problem there is augmented by an increasing incidence of diabetes in the population. An appropriate drug/gene delivery system that can sustain and deliver therapeutics to the target tissues and cells is a key need for ocular therapies. The application of nanotechnology in medicine is undergoing rapid progress, and the recent developments in nanomedicine-based therapeutic approaches may bring significant benefits to address the leading causes of blindness associated with cataract, glaucoma, diabetic retinopathy and retinal degeneration. In this brief review, we highlight some promising nanomedicine-based therapeutic approaches for drug and gene delivery to the anterior and posterior segments.

KEYWORDS:

Age-Related Macular Degeneration; Dendrimers; Nanoparticles; Ocular Gene Therapy; Targeted Therapies

PMID:
23580849
PMCID:
PMC3617524
DOI:
10.4103/0974-9233.106384
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center